Loading
Pumitamig / Pembrolizumab / Carboplatin · Phase 2/3 Trial
ClinicalTrials.gov · August 13, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a prospectively registered Phase 2/3 trial of BNT327 (pumitamig) combined with chemotherapy and pembrolizumab in first-line non-small cell lung cancer, currently recruiting. No efficacy or safety results are reported in this registry record; outcomes remain unassessed pending trial completion.
Phase 2/3, Interventional, Randomized, Sequential, Open label, Treatment purpose. Non-small Cell Lung Cancer; age from 18 Years. Intervention: Substudy A Phase 2 (Arm 1) - Pumitamig Dose 1 + Carboplatin…; Substudy A Phase 2 (Arm 2) - Pumitamig Dose 2 + Carboplatin…; Substudy A Phase 2 (Arm 1A - China only) - Pumitamig Dose 3…; Substudy A Phase 3 (Arm 3) - Pumitamig Dose 3 + Carbo…. Compared with: Substudy A Phase 3 (Arm 4) - Pembrolizumab + Carboplatin +… — Active Comparator; Substudy B Phase 3 (Arm 4) - Pembrolizumab + Carboplatin +… — Active Comparator. n = 1,580. 261 sites across 20 countries.
This is a prospectively registered Phase 2/3 trial of BNT327 (pumitamig) combined with chemotherapy and pembrolizumab in first-line non-small cell lung cancer, currently recruiting. No efficacy or safety results are reported in this registry record; outcomes remain unassessed pending trial completion.
No efficacy or safety results reported; study is currently recruiting.
No clinical impact can be assessed from this registry record. Results from Phase 2 safety and efficacy analyses, and Phase 3 PFS data, are needed before clinical recommendations can be made.
This is a recruiting Phase 2/3 trial registration with no reported results; primary outcomes remain unassessed and data are not yet available to evaluate efficacy or safety.
As stated by the source record.
Quoted from the source exactly as published.
No clinical impact can be assessed from this registry record. Results from Phase 2 safety and efficacy analyses, and Phase 3 PFS data, are needed before clinical recommendations can be made.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06712316). This is a study registration, not published results. Lead sponsor: BioNTech SE. Recruitment status: RECRUITING. Phase: PHASE2, PHASE3. Study type: INTERVENTIONAL. Enrollment: 1580 participants (ESTIMATED). Conditions: Non-small Cell Lung Cancer. Interventions: DRUG: Pumitamig; DRUG: Pembrolizumab; DRUG: Carboplatin; DRUG: Pemetrexed; DRUG: Paclitaxel. Primary outcome measures: Phase 2 - Occurrence of treatment-emergent adverse events (TEAE) (including Grade ≥3), adverse events of special interest (AESIs), treatment-related TEAEs, treatment-emergent serious adverse events (SAE), and treatment-related treatment emergent SAEs , From the first dose of the investigational medicinal product (IMP) to the 90-day Follow-Up Visit; Phase 2 - Occurrence of dose interruption, reduction, and discontinuation of IMP due to TEAEs (including related TEAEs) , From the first dose of IMP to the 90-day Follow-Up Visit; Phase 2 - Objective response rate (ORR) , Up to approximately 2 years; Phase 2 - Best percentage change from baseline in tumor size , Up to approximately 2 years; Phase 3 - Progression free survival (PFS) assessed by BICR , Up to approximately 5 years. Brief summary: This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to histological subtypes due to differences in chemotherapy choice for standard-of-care and type of NSCLC.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.